Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.

ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy for hematologic malignancies is fraught with several unknowns, including number of functional T cells that engage target tumor, durability and subsequent expansion and contraction of that engagement, and whether toxicity can be managed. Non-invasive, serial imaging of CAR T cell therapy using a reporter transgene can address those issues quantitatively. We have transduced anti-CD19 CAR T cells with the prostate-specific membrane antigen (PSMA) because it is a human protein with restricted normal tissue expression and has an expanding array of positron emission tomography (PET) and therapeutic radioligands. We demonstrate that CD19-tPSMA^(N9del) CAR T cells can be tracked with [¹⁸F]DCFPyL PET in a Nalm6 model of acute lymph

SUBMITTER: Minn I 

PROVIDER: S-EPMC6609218 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature